The central cannabinoid receptor type-2 (CB2) and chronic pain

References

• Kress M, Kuner R. Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res 2009;196:79–88.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Onaivi ES, Chaudhuri G. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq 1995;5:385–8.
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–4.
   PubMed Web of Science ®Google Scholar
• Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996;393:231–5.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Bari M, Battista N, et al. Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 2002;1:53–63.
   PubMedGoogle Scholar
• Lauckner JE, Jensen JB, Chen HY, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 2008;105:2699–704.
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Höglund PJ, Gloriam DE, et al. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 2003;554:381–8.
   PubMed Web of Science ®Google Scholar
• McHugh D, Hu SS, Rimmerman N, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 2010;11:44.
   PubMed Web of Science ®Google Scholar
• Yoon MH, Choi JI. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 2003;99:701–7.
   PubMed Web of Science ®Google Scholar
• Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004;109:124–31.
   PubMed Web of Science ®Google Scholar
• Malan TPJr, Ibrahim MM, Lai J, et al. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003;3:62–7.
   PubMed Web of Science ®Google Scholar
• Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol 2005;69:1705–13.
   PubMed Web of Science ®Google Scholar
• Valenzano KJ, Tafesse L, Lee G, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005;48:658–72.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Melck D, Bobrov MYu, et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000;351:817–24.
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–9.
   PubMed Web of Science ®Google Scholar
• Hanus L, Abu-Lafi S, Fride E, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001;98:3662–5.
   PubMed Web of Science ®Google Scholar
• Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002;301:1020–4.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89–97.
   PubMed Web of Science ®Google Scholar
• Campillo NE, Páez JA. Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. Mini Rev Med Chem 2009;9:539–59.
   PubMed Web of Science ®Google Scholar
• Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539–48.
   PubMed Web of Science ®Google Scholar
• Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007;150:613–23.
   PubMed Web of Science ®Google Scholar
• Thomas A, Stevenson LA, Wease KN, et al. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 2005;146:917–26.
   PubMed Web of Science ®Google Scholar
• Little PJ, Compton DR, Johnson MR, et al. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 1988;247:1046–51.
   PubMed Web of Science ®Google Scholar
• Little PJ, Compton DR., Mechoulam R, et al. Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 1989;32:661–6.
   PubMed Web of Science ®Google Scholar
• Huffman JW, Liddle J, Yu S, et al. 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 1999;7:2905–14.
   PubMed Web of Science ®Google Scholar
• Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 1999;96:14228–33.
   PubMed Web of Science ®Google Scholar
• Huffman JW, Bushell SM, Joshi SN, et al. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg Med Chem 2006;14:247–62.
   PubMed Web of Science ®Google Scholar
• Hsieh GC, Pai M, Chandran P, et al. Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 2011;162:428–40.
   PubMed Web of Science ®Google Scholar
• Mazzari S, Canella R, Petrelli L, et al. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996;300:227–36.
   PubMed Web of Science ®Google Scholar
• Malan TP, Ibrahim MM, Deng H, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001;93:239–45.
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Deng H, Zvonok Aet al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003;100:10529–33.
   Google Scholar
• Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003;119:747–57.
   PubMed Web of Science ®Google Scholar
• Yao BB, Mukherjee S, Fan Y, et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 2006;149:145–54.
   PubMed Web of Science ®Google Scholar
• Song ZH, Slowey CA, Hurst DP, et al. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol Pharmacol 1999;56:834–40.
   PubMed Web of Science ®Google Scholar
• Gonsiorek W, Lunn CA, Fan X, et al. Sch 35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br J Pharmacol 2007;151:1262–71.
   PubMed Web of Science ®Google Scholar
• Giblin GM, O'Shaughnessy CT, Naylor A, et al. Discovery of 2- [(2,4-dichlorophenyl)amino]-N- [(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 2007;50:2597–600.
   PubMed Web of Science ®Google Scholar
• Brown SM, Wager-Miller J, Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 2002;1576:255–64.
   PubMed Web of Science ®Google Scholar
• Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. J Pharmacol ExpTher 2000;292:886–94.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–5.
   PubMed Web of Science ®Google Scholar
• Ständer S, Schmelz M, Metze D, et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005;38:177–88.
   PubMed Web of Science ®Google Scholar
• Ashton JC, Friberg D, Darlington CL, et al. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 2006;396:113–6.
   PubMed Web of Science ®Google Scholar
• Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006;1071:10–23.
   PubMed Web of Science ®Google Scholar
• Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996;93:3984–9.
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329–32.
   PubMed Web of Science ®Google Scholar
• Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010;160:467–79.
   PubMed Web of Science ®Google Scholar
• Maresz K, Carrier EJ, Ponomarev ED, et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005;95:437–45.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hoffert C, Vu HK, et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003;17:2750–4.
   PubMed Web of Science ®Google Scholar
• Solas M, Francis PT, Franco R, et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging 2013;34:805–8.
   PubMed Web of Science ®Google Scholar
• Benito C, Kim WK, Chavarria I, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci Off J Soc Neurosci 2005;25:2530–6.
   PubMed Web of Science ®Google Scholar
• Sheng WS, Hu S, Min X, et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005;49:211–9.
   PubMed Web of Science ®Google Scholar
• Golech SA, McCarron RM, Chen Y, et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 2004;132:87–92.
   PubMedGoogle Scholar
• Glass M, Northup JK. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 1999;56:1362–9.
   PubMed Web of Science ®Google Scholar
• Lauckner JE, Hille B, Mackie K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 2005;102:19144–9.
   PubMed Web of Science ®Google Scholar
• Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995;48:443–50.
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Poinot-Chazel C, Marchand J, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996;237:704–11.
   PubMedGoogle Scholar
• Grigorenko E, Kittler J, Clayton C, et al. Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem Phys Lipids 2002;121:257–66.
   PubMed Web of Science ®Google Scholar
• Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773–8.
   PubMed Web of Science ®Google Scholar
• Ribeiro R, Wen J, Li S, et al. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat 2013;100–101:1–14.
   PubMed Web of Science ®Google Scholar
• Atwood BK, Wager-Miller J, Haskins C, et al. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol 2012;81:250–63.
   PubMed Web of Science ®Google Scholar
• Beltramo M. The cannabinoid system and pain: towards new drugs? J Société Biol 2009;203:99–106.
   PubMedGoogle Scholar
• Franklin JM, Vasiljevik T, Prisinzano TE, et al. Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors. Eur Neuropsychopharmacol 2013;23:760–7.
   PubMed Web of Science ®Google Scholar
• Franklin JM, Carrasco GA. Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex. J Psychopharmacol 2012;26:1333–47.
   PubMed Web of Science ®Google Scholar
• Hulsebosch CE. Special issue on microglia and chronic pain. Exp Neurol 2012;234:253–4.
   PubMed Web of Science ®Google Scholar
• Sun L, Wu Z, Hayashi Y, et al. Microglial cathepsin B contributes to the initiation of peripheral inflammation-induced chronic pain. J Neurosci 2012;32:11330–42.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Terayama R, Kishimoto N, et al. Activated microglia contribute to convergent nociceptive inputs to spinal dorsal horn neurons and the development of neuropathic pain. Neurochem Res 2015;40:1000–12.
   PubMed Web of Science ®Google Scholar
• Mueller M, Wacker K, Ringelstein EB, et al. Rapid response of identified resident endoneurial macrophages to nerve injury. Am J Pathol 2001;159:2187–97.
   PubMed Web of Science ®Google Scholar
• Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol 1999;157:289–304.
   PubMed Web of Science ®Google Scholar
• Qin M, Wang JJ, Cao R, et al. The lumbar spinal cord glial cells actively modulate subcutaneous formalin induced hyperalgesia in the rat. Neurosci Res 2006;55:442–50.
   PubMed Web of Science ®Google Scholar
• Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. Brain 2015;138:604–15.
   PubMed Web of Science ®Google Scholar
• Raghavendra V, Tanga FY, DeLeo JA. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004;20:467–73.
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Cinci L, Micheli L, et al. α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement. Pain 2014;155:1986–95.
   PubMed Web of Science ®Google Scholar
• LeBlanc BW, Zerah ML, Kadasi LM, et al. Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatic neuropathy. Neurosci Lett 2011;498:138–42.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zhou LJ, Ren WJ, et al. The direction of synaptic plasticity mediated by C-fibers in spinal dorsal horn is decided by Src-family kinases in microglia: the role of tumor necrosis factor-alpha. Brain Behav Immun 2010;24:874–80.
   PubMed Web of Science ®Google Scholar
• Daulhac L, Mallet C, Courteix C, et al. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 2006;70:1246–54.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Ueno H, Kataoka A, et al. Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. Glia 2008;56:378–86.
   PubMed Web of Science ®Google Scholar
• Wodarski R, Clark AK, Grist J, et al. Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur J Pain Lond Engl 2009;13:807–11.
   PubMed Web of Science ®Google Scholar
• Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007;203:42–54.
   PubMed Web of Science ®Google Scholar
• Bethea JR, Castro MC, Lee TT, et al. Traumatic spinal cord injury induces nuclear factor kappa-B activation. J Neurosci 1998;18:3251–60.
   PubMed Web of Science ®Google Scholar
• Paszcuk AF, Dutra RC, da Silva KA, et al. Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases. PloS One 2011;6:e24034.
   PubMed Web of Science ®Google Scholar
• Romero-Sandoval A, Eisenach JC. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007;106:787–94.
   PubMed Web of Science ®Google Scholar
• Brownjohn PW, Ashton JC. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury. Neuroscience 2012;203:180–93.
   PubMed Web of Science ®Google Scholar
• Milne M, Ashton JC. Effect of cannabinoids on CGRP release in the isolated rat lumbar spinal cord. Neurosci Lett 2016;614:39–42.
   PubMed Web of Science ®Google Scholar
• Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006;49:67–79.
   PubMed Web of Science ®Google Scholar
• Beltramo M, Bernardini N, Bertorelli R, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006;23:1530–8.
   PubMed Web of Science ®Google Scholar
• Elmes SJ, Winyard LA, Medhurst SJ, et al. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005;118:327–35.
   PubMed Web of Science ®Google Scholar
• Yamamoto W, Mikami T, Iwamura H. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 2008;583:56–61.
   PubMed Web of Science ®Google Scholar
• Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008;108:722–34.
   PubMed Web of Science ®Google Scholar
• Naguib M, Diaz P, Xu JJ, et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 2008;155:1104–16.
   PubMed Web of Science ®Google Scholar
• Xu JJ, Diaz P, Astruc-Diaz F, et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg 2010;111:99–109.
   PubMed Web of Science ®Google Scholar
• McGaraughty S, Chu KL, Dart MJ, et al. A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors. Neuroscience 2009;158:1652–61.
   PubMed Web of Science ®Google Scholar
• Hu B, Doods H, Treede RD, et al. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 2009;143:206–12.
   PubMed Web of Science ®Google Scholar
• Bujalska-Zadrożny M, de Cordé A, Pawlik K. Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. Pharmacol Rep 2015;67:209–16.
   PubMed Web of Science ®Google Scholar
• Curto-Reyes V, Llames S, Hidalgo A, et al. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 2010;160:561–73.
   PubMed Web of Science ®Google Scholar
• Rahn EJ, Zvonok AM, Thakur GA, et al. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008;327:584–91.
   PubMed Web of Science ®Google Scholar
• Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003;23:1398–405.
   PubMed Web of Science ®Google Scholar
• Toth CC, Jedrzejewski NM, Ellis CL, et al. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain 2010;6:16.
   PubMed Web of Science ®Google Scholar
• Ulugol A, Karadag HC, Ipci Y, et al. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004;371:167–70.
   PubMed Web of Science ®Google Scholar
• Cui JH, Kim WM, Lee HG, et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Neurosci Lett 2011;493:67–71.
   PubMed Web of Science ®Google Scholar
• Potenzieri C, Harding-Rose C, Simone DA. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008;1215:69–75.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797–805.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993;11:2010–20.
   PubMed Web of Science ®Google Scholar
• Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152:765–77.
   PubMed Web of Science ®Google Scholar
• Pascual D, Goicoechea C, Suardíaz M, et al. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005;118:23–34.
   PubMed Web of Science ®Google Scholar
• Koltyn KF, Brellenthin AG, Cook DB, et al. Mechanisms of exercise-induced hypoalgesia. J Pain Off J Am Pain Soc 2014;15:1294–304.
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290–6.
   PubMed Web of Science ®Google Scholar
• Page SA, Verhoef MJ, Stebbins RA, et al. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003;30:201–5.
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812–9.
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664–9.
   PubMed Web of Science ®Google Scholar
• Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337–41.
   PubMed Web of Science ®Google Scholar
• Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med Malden Mass 2006;7:25–9.
   PubMed Web of Science ®Google Scholar
• Frank B, Serpell MG, Hughes J, et al. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336:199–201.
   PubMed Web of Science ®Google Scholar
• Noyes R, Brunk SF, Avery DA, et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84–9.
   PubMed Web of Science ®Google Scholar
• Jochimsen PR, Lawton RL, VerSteeg K, et al. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978;24:223–7.
   PubMed Web of Science ®Google Scholar
• Maida V, Ennis M, Irani S, et al. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 2008;6:119–24.
   PubMedGoogle Scholar
• Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain – a randomized controlled trial. Wien Klin Wochenschr 2006;118:327–35.
   PubMed Web of Science ®Google Scholar
• Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:E694–701.
   PubMed Web of Science ®Google Scholar
• Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290:1757–62.
   PubMed Web of Science ®Google Scholar